Indeed, vaccination with NY-ESO-1-based formulations administered alone or in combination with adjuvants [7,8] or checkpoint inhibitors [9] induced both humoral and cellular anti-tumor responses in clinical trials; thus, the NY-ESO-1 antigen is often included in multi-epitope cancer vaccines [10]. The gene discussed is CTAG1B; the disease is neoplasm.